FDA Approves New GLP-1 Weight Loss Pill with Fewer Usage Restrictions
The U.S. Food and Drug Administration has cleared a second oral GLP-1 medication for weight loss. The drug, orforglipron, will be marketed by Eli Lilly as Foundayo. This approval marks another shift in obesity treatment options.
What the approval means
The FDA approves a new GLP-1 pill for weight loss that carries fewer usage restrictions than some competitors. Foundayo can be taken at any time of day. It does not require fasting or pre-dose water rules.
That contrasts with the recently approved oral form of Wegovy. The Wegovy pill must be taken first thing in the morning and 30 minutes before food or drink.
Companies and competing products
Eli Lilly already markets injectable GLP-1s, including Zepbound for obesity and Mounjaro for diabetes. Novo Nordisk sells injectables such as Wegovy and Ozempic. Both companies are now offering pill versions of GLP-1 therapies.
Industry estimates show rapid uptake of oral GLP-1 medicines. One Wall Street firm estimated as many as 400,000 U.S. users of the Wegovy pill so far.
Clinical results and switching studies
Foundayo is approved for adults with obesity or overweight and weight-related conditions like high blood pressure. In the pivotal trial, the highest dose produced about 12% average weight loss at 72 weeks.
By comparison, injectable GLP-1 drugs have produced trial weight losses exceeding 20 percent. Novo Nordisk reported up to 17% average loss on its highest oral Wegovy dose.
Switching from injections
Lilly tested patients who transitioned from injectables to the pill. Those switching from the injectable Wegovy regained about 0.9 kilograms on average. Patients who switched from Zepbound regained roughly 5 kilograms on average.
Safety and common side effects
The most frequent adverse effects mirror other GLP-1 medicines. Patients reported nausea, constipation and other gastrointestinal symptoms. Some experienced hair loss.
Foundayo is approved only for adults. Its safety in children and during pregnancy has not been established. Lilly warns that birth control pills may be less effective while taking the drug.
Pricing, coverage and availability
Pills in the new class have prompted new pricing arrangements. Under a November agreement, manufacturers offer low introductory prices starting at $149 a month for the lowest doses. Foundayo’s top out-of-pocket price will reach $349 per month.
Lilly said a refill within 45 days lowers that top price to $299 a month. The company will offer a coupon for commercially insured patients, reducing some copays to about $25 per month.
Medicare coverage for some patients is expected with a monthly copay capped at $50. That benefit begins on July 1 under the announced program.
Rollout
Lilly will provide free home shipping through its LillyDirect service starting April 6. Pharmacy and telehealth availability will follow soon after. Novo Nordisk has also announced subscription and tiered pricing for its oral product.
Regulatory pace
The FDA completed its review of Foundayo in 50 days. The review used a pilot priority voucher program run by the Commissioner. That timeline makes this the fastest approval for a new molecular entity since 2002.
Filmogaz.com will continue to track developments in GLP-1 therapies and access programs. The arrival of additional oral options adds new choices for patients and clinicians.
